 |
Vol.43 No.7 contents | Japanese/English |
 | Full Text of PDF (41K) Article in Japanese |
- -
Non-platinum Gemcitabine-based Combination Chemotherapy
Kaoru Kubota1Purpose. To evaluate the role of non-platinum, gemcitabine-based combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC). Method. Clinical trials of gemcitabine plus vinorelbine and gemcitabine plus docetaxel which were published in peer-review journals were reviewed in terms of efficacy and toxicity. Results. A phase III trial comparing gemcitabine plus vinorelbine with cisplatin-based regimens demonstrated a non-significant slight survival disadvantage with gemcitabine plus vinorelbine.Global QoL is not improved with gemcitabine plus vinorelbine, although it is less toxic than cisplatin-based regimens.A randomized trial comparing docetaxel plus gemcitabine with cispaltin plus docetaxel demonstrated similar response rate, time to tumor progression, overall survival, and two-year survival rate. Conclusion. Gemcitabine-based two drug combination is active in patients with advanced NSCLC with less gastrointestinal toxicity than standard cisplatin-based chemotherapy. Non-platinum gemcitabine-based chemotherapy could be a treatment option in patients with advanced NSCLC.
key words: Lung cancer, Chemotherapy, Gemcitabine, Vinorelbine, Docetaxel
JJLC 43 (7): 912-915, 2003
